Hikma Highlights Long-Term Importance Of Biosimilars

CEO Siggi Olafsson Discusses The Evolution Of Hikma’s Injectables Business

 
• By David Wallace
  
Timeline years 2025 blue pin
Hikma sees biosimilars becoming a significant part of its business from 2025 • Source: Olivier Le Moal / Alamy Stock Photo
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products